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Background: Scleroderma renal crisis is an important complication of scleroderma (systemic sclerosis) that is
associated with significant morbidity and mortality. On the other hand, hyponatremia has never been reported in
patients with scleroderma renal crisis.
Case presentation: A 66-year-old man with scleroderma was admitted to our hospital for an evaluation of renal
dysfunction and extreme hypertension. The laboratory evaluation revealed remarkably high plasma renin activity in
association with microangiopathic hemolytic anemia, and the anti-RNA polymerase III antibody assessment was
positive. The patient was diagnosed with scleroderma renal crisis and was started treatment with enalapril maleate,
an angiotensin-converting enzyme inhibitor. During hospitalization, the patient developed symptomatic
hyponatremia three times and each laboratory analysis revealed improperly high levels of antidiuretic hormone
without signs of extracellular fluid volume depletion as well as remarkably high plasma renin activities and
angiotensin levels. However, hyponatremia has not been demonstrated to occur as a result of combined therapy
with candesartan cilexetil, an angiotensin II receptor blocker, and aliskiren fumarate, a direct renin inhibitor. The
plasma renin activities and angiotensin levels were normalized and the renal function was maintained after
treatment.
Conclusions: To our best knowledge, this is the first documented case of scleroderma renal crisis complicated with
hyponatremia. This report also suggests that the activated renin-angiotensin system may play a role in the
development of hyponatremia and that hyponatremia should be taken into consideration as a rare but possible
complication associated with screloderma renal crisis.
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Scleroderma renal crisis (SRC) is an important complica-
tion of scleroderma (systemic sclerosis) that is associated
with significant morbidity and mortality [1]. Strikingly
high levels of plasma renin activity are typically observed
accompanying malignant hypertension and it is almost
certain that the renin-angiotensin system (RAS) plays a
central role in the pathophysiology of SRC. In the late
1970s, angiotensin-converting enzyme (ACE) inhibitors
were introduced, and these inhibitors have dramatically
improved the outcomes of patients with SRC [2].* Correspondence: hfukasawaucsd@gmail.com
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reproduction in any medium, provided the orHyponatremia is the most common electrolyte dis-
order seen in clinical practice [3]. To date, it has been
reported that certain ACE inhibitors can cause hypona-
tremia, although the precise mechanism responsible
remains to be elucidated [4].
Here, we report a rare case of SRC complicated with
hyponatremia. We also describe the potential relation-
ship between a highly activated RAS and the develop-
ment of hyponatremia.
Case presentation
A 66-year-old man with a 10-year history of scleroderma
was admitted to our hospital for an evaluation of renal
dysfunction and accelerated hypertension in May
2010. His renal function and blood pressure hadral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pressure was 240/128 mmHg and he had hypertensive
retinopathy with Keith-Wagner grade III fundoscopic
changes, sclerodactyly and superficial ulcers of the finger-
tips. A laboratory evaluation revealed the following: a blood
urea nitrogen (BUN) level of 71 mg/dl (25.3 mmol/L), a
serum creatinine level of 4.69 mg/dl (414.6 μmol/L) and a
plasma renin activity above 20 ng/ml/hr (above 5.56 ng/L/s,
normal range 0.9–2.9 ng/ml/hr) with microangiopathic
hemolytic anemia. In addition, the anti-RNA polymerase III
antibody test was positive, but the anti-Scl-70 (topoisomer-
ase I) antibody test was negative. From these findings, we
diagnosed this patient as having SRC and he was immedi-
ately treated with the ACE inhibitor, enalapril maleate
(Enalapril) at 10 mg/day. After starting the treatment, his
blood pressure decreased and renal dysfunction partially
improved (Figure 1).
On the 8th day of hospitalization, his consciousness
suddenly deteriorated and urgent laboratory findings
revealed that his serum sodium level had decreased from
131 mEq/L (131 mmol/L) at the time of admission to
116 mEq/L (116 mmol/L), his urine osmolarity
(332 mOsm/kg =mmol/kg) was greater than his serum
osmolarity (261 mOsm/kg) and the level of antidiuretic
hormone (ADH) was 6.1 pg/ml (5.6 pmol/L), which wasFigure 1 Clinical course. The patient was initially treated with
enalapril maleate (Enalapril) for SRC. On the 8th day of
hospitalization, the patient’s consciousness deteriorated and the
serum sodium level was dropped to 116 mEq/L. The level of
antidiuretic hormone (ADH) was inappropriately high for the serum
osmolarity. The plasma renin activity and angiotensin I level were
also extremely high on the same day (see Table 1). After the switch
from Enalapril to candesartan cilexetil (Candesartan) due to skin
eruptions, hyponatremia similarly developed on 40th and 60th days
of hospitalization, respectively. Laboratory data also revealed
improperly high levels of ADH, extremely high plasma renin
activities and high angiotensin levels. However, hyponatremia had
not occurred after the increased dose of Candesartan and the
addition of aliskiren fumarate (Aliskiren). The plasma renin activity
and angiotensin levels were normalized (see Table 1) and the renal
function was preserved. Conversion factors for units: serum
creatinine in mg/dl to μmol/L, x 88.4. No conversion is necessary for
serum sodium in mEq/L and mmol/L.improperly high for the indicated serum osmolarity. His
thyroid function was normal and adrenal insufficiency
was ruled out. There were no signs of extracellular fluid
volume depletion and the results of a brain computed
tomography (CT)-scan were normal. Although these
data indicated that his hyponatremia was caused via the
improper secretion of ADH, the patient did not fulfill
the criteria for a diagnosis of the syndrome of inappro-
priate secretion of ADH (SIADH) due to the co-
existence of renal dysfunction. It was also found that the
plasma renin activity and angiotensin I levels were ex-
tremely high on the 8th day of hospitalization (Table 1).
His hyponatremia was treated with water restriction and
with the infusion of hypertonic saline.
On the 19th day of hospitalization, he exhibited skin
eruptions that were an adverse effect of the Enalapril
treatment. Then, Enalapril was replaced with candesar-
tan cilexetil (Candesartan) at a dose of 4 mg/day. After
this replacement with Candesartan, he developed hypo-
natremia twice with similar symptoms on the 40th and
60th day of hospitalization, respectively (Figure 1).
Laboratory data also revealed improperly high levels of
ADH, extremely high plasma renin activity and high
angiotensin levels on the 40th and 60th day of
hospitalization (Table 1). However, after the dose of
Candesartan was increased to 12 mg/day and aliskiren
fumarate (Aliskiren) at 300 mg/day was also included in
the treatment regimen, his serum sodium levels were
normalized and were maintained within the normal
range thereafter. His plasma renin activity and angioten-
sin levels were also normalized and his renal function
was preserved.
Conclusions
Here, we report a rare case of SRC complicated with
hyponatremia. To our best knowledge, this is the first
case to be described in the literature. Each episode of
hyponatremia was accompanied with improperly high
levels of ADH, extremely high plasma renin activities
and high angiotensin levels without signs of extracellular
fluid volume depletion. Furthermore, hyponatremia was
prevented via the strong blockade of RAS using a thera-
peutic combination of the angiotensin II receptor
blocker, Candesartan, and the direct renin inhibitor,
Aliskiren. Then, it was suggested that the activated RAS
might have played an important role in the development
of this case of hyponatremia.
To date, there is clear evidence supporting the existence
of the central RAS, which is independent of the peripheral
RAS [5,6]. Moreover, mechanisms and components
required for the formation of angiotensin II have been
identified in the brain [6,7]. In accordance with these find-
ings, it has been reported that peripheral angiotensins
were unable to penetrate the blood–brain barrier (BBB)
Table 1 Levels of serum sodium, RAS components and ADH at the time of and after admission
On admission Day 8 (1st) Day 40 (2nd) Day 60 (3rd) Day 110
Medication Enalapril Candesartan 4 mg Candesartan 8 mg Candesartan 12 mg+Aliskiren
Sodium (mEq/L) 131 116 120 124 136
Renin (0.3-2.9 ng/ml/hr) > 20 > 20 > 20 > 20 2.2
Angiotensin I (< 110 pg/ml) 210 1100 350 560 < 30
Angiotensin II (< 22 pg/ml) 330 41 1500 1100 27
Aldosterone (2.9-15.9 ng/dl) 18.5 14.0 14.0 7.87 3.87
ADH (pg/ml) Not determined 6.1 0.9 1.0 Not determined
Serum creatinine (mg/dl) 4.69 5.03 5.58 6.06 6.04
Body weight (kg) Not determined 49.1 46.9 48.1 46.1
Definition of the abbreviations: RAS, renin-angiotensin system, ADH, antidiuretic hormone, Renin, plasma renin activity. Numerical values in each parenthesis
indicate normal values.
Note: Conversion factors for units: plasma renin activity in ng/ml/hr to ng/L/s, x 0.2778; angiotensin I in pg/ml to fmol/ml, x 0.772; angiotensin II in pg/ml to
fmol/ml, x 0.956; aldosterone in ng/dl to nmol/L, x 0.02774; ADH in pg/ml to pmol/L, x 0.923; serum creatinine in mg/dl to mmol/L, x 88.4. No conversion is
necessary for serum sodium in mEq/L and mmol/L.
Figure 2 Diagram of the potential relationship between
peripheral and central renin-angiotensin systems and ADH
secretion. Angiotensin II (ANGII) in the peripheral circulation is
accessible to circumventricular organs (CVOs), which lack the blood–
brain barrier (BBB). Within CVOs, high levels of ANGII (for example,
via the infusion of ANGII) can stimulate the ADH secretion via ANGII
receptors in the brain. Most of the blood-borne angiotensin I (ANG I)
is converted into ANGII at the lungs by the angiotensin-converting
enzyme (ACE) under physiological conditions, although the rate of
this conversion process is decreased under pathological conditions.
Because the activity of ACE in CVOs is much higher than that in the
lungs, the redundant ANG I may be converted to ANGII locally and
this converted (and high levels of) ANGII may then stimulate the
ADH secretion.
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reported that Enalapril [9], Candesartan [8] and Aliskiren
(unpublished data by Novartis Pharmaceuticals Corpor-
ation) were unable to penetrate the BBB.
On the other hand, it has been reported that high
levels of angiotensin II in the peripheral circulation (for
example, via the infusion of angiotensin II) could affect
the central actions including the secretion of ADH [10].
The effects of high levels of angiotensin II on the
hypothalamic-neurohypophysial system are mediated via
circumventricular organs (CVOs), such as the subforni-
cal organ and the organum vasculosum of the lamina
terminalis. These organs anatomically lack the BBB, and
as a result, angiotensins in the peripheral circulation are
accessible to these sites [11]. Accordingly, it is likely that
supra-physiological levels of angiotensin II were involved
in the improper secretion of ADH resulting from the
anatomical characteristics of CVOs and these factors
subsequently led the development of hyponatremia in
our case (Figure 2).
Circulating angiotensin I is converted into angiotensin
II by ACE mainly in the lungs, and ACE inhibitors can
block this conversion process. In fact, the level of angio-
tensin I, but not angiotensin II, was remarkably high at
the time when the first episode of hyponatremia devel-
oped on the 8th day of hospitalization, because the pa-
tient was treated with Enalapril, an ACE inhibitor
(Table 1). Interestingly, much higher ACE activities have
been identified in CVOs compared to those in lungs [12]
and Thunhorst et al. [13] showed that the peripheral
ACE blockade with anti-hypertensive doses could not in-
hibit the ACE activities in CVOs. Therefore, it was pos-
sible that the remarkably high levels of angiotensin I
reached in CVOs were locally converted into angiotensin
II, that the converted (and likely high levels of ) angio-
tensin II stimulated ADH secretion, and that the firstepisode of hyponatremia finally developed on the 8th day
of hospitalization.
However, we cannot exclude the following alternative
possibilities: (i) that the disturbance of free water
excretion due to renal dysfunction co-existed also played
a role in the development of hyponatremia and (ii) that
the permeability of the BBB for angiotensins was altered
due to the pathological condition of SRC.
In conclusion, we experienced this rare case of SRC
complicated with hyponatremia. Further studies are
required to clarify the precise mechanism responsible
for the association between SRC and hyponatremia,
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in the development of hyponatremia in this case.
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